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ABSTRACT
Background. Elderly patients with pancreatic cancer are
underrepresented in clinical trials, resulting in a lack of
evidence.
Objective. The aim of this study was to compare treatment
and overall survival (OS) of patients aged C 70 years with
stage I–II pancreatic cancer in the EURECCA Pancreas
Consortium.
Methods. This was an observational cohort study of the
Belgian (BE), Dutch (NL), and Norwegian (NOR) cancer
registries. The primary outcome was OS, while secondary
outcomes were resection, 90-day mortality after resection,
and (neo)adjuvant and palliative chemotherapy.
Results. In total, 3624 patients were included. Resection
(BE: 50.2%; NL: 36.2%; NOR: 41.3%; p\ 0.001), use of
(neo)adjuvant chemotherapy (BE: 55.9%; NL: 41.9%;
NOR: 13.8%; p\ 0.001), palliative chemotherapy (BE:
39.5%; NL: 6.0%; NOR: 15.7%; p\ 0.001), and 90-day
mortality differed (BE: 11.7%; NL: 8.0%; NOR: 5.2%;
p\ 0.001). Furthermore, median OS in patients with (BE:
17.4; NL: 15.9; NOR: 25.4 months; p\ 0.001) and with-
out resection (BE: 7.0; NL: 3.9; NOR: 6.5 months;
p\ 0.001) also differed.
Conclusions. Differences were observed in treatment and
OS in patients aged C 70 years with stage I–II pancreatic
cancer, between the population-based cancer registries.
Future studies should focus on selection criteria for
(non)surgical treatment in older patients so that clinicians
can tailor treatment.
For pancreatic cancer, very little progress has been made
in terms of mortality rates over the past decades.1 Resec-
tion combined with systemic treatment offers the best
chance for prolonged survival. Resectability is mainly
determined by contact between the tumor and the venous
and arterial vasculature.2 Patients with stage I–II pancreatic
cancer are generally considered eligible for resection. Un-
fortunately, about 20% of all patients are resectable due to
advanced or metastatic disease at diagnosis.3 Still, even
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after tumor resection of stage I–II pancreatic cancer,
prognosis is poor, with a median overall survival (OS) of
17–30 months.4
The most recent European Society of Medical Oncology
(ESMO) guideline does not consider advanced age a con-
traindication for resection, but states that comorbidities and
poor functional status can be a reason to refrain from
resection.5 The National Comprehensive Cancer Network
(NCCN) guideline is largely similar to the ESMO guide-
line.6 Although no statements are made regarding advanced
age directly, the guideline states that performance status
should be taken into account when considering treatment
strategy. Older cancer patients are often underrepresented
in clinical trials, possibly due to the strict inclusion crite-
ria.7 Recently, a study with population-based data of
multiple pancreatic cancer registries showed that the
median age at diagnosis is 70 years.8 This clearly differs
from large randomized controlled trials in pancreatic can-
cer in which the median age is 61–65 years.9–12 There is a
lack of evidence on treatment and survival of elderly
patients with pancreatic cancer.
The EUropean REgistration of Cancer CAre (EUR-
ECCA) consortium, established by the European CanCer
Organisation (ECCO), investigates differences in treatment
and outcomes of patients in a real-world scenario by using
cancer registry data.13 Previous studies from the EUR-
ECCA Pancreas Consortium showed considerable
variations in treatment and outcomes.14,15
The aim of this study was to compare treatment strate-
gies and survival outcomes of patients aged C 70 years
with stage I–II pancreatic cancer in the Belgian (BE),
Dutch (NL), and Norwegian (NOR) national cancer reg-
istries from the EURECCA Pancreas Consortium.
METHODS
Design and Patient Selection
This was an observational cohort study of three cancer
registries in the EURECCA Pancreas Consortium reported
according to the Strengthening the Reporting of Observa-
tional Studies (STROBE) criteria.16 The BE, NL, and NOR
national cancer registries were selected because of data
quality, data availability, and similarity regarding design
and organization (electronic supplementary Table S1). In
addition, cancer incidence and life expectancy are largely
similar between these national cancer registries.17 Patients
aged C 70 years with pancreatic adenocarcinoma stage I–
II, diagnosed from 2012 through 2016 (2012 through 2015
for BE), were included. Patients aged C 70 years were
included according to the definitions of ‘elderly’ of the
International Society of Geriatric Oncology (http://siog.or
g/content/defining-elderly). An overview of stage distri-
bution per cancer registry is provided in electronic
supplementary Table S2. Patients with other malignancies
were not excluded because pancreatic cancer is often
determinative for the prognosis. In case of synchronous
pancreatic cancer, the tumor with the highest known stage
was used.
Data Collection, Definition, and Preparation
Anonymous data obtained from the cancer registries
included (1) patient- and tumor-related variables, i.e. sex,
age, tumor topography, tumor morphology, tumor stage;
(2) treatment-related variables, i.e. tumor resection,
chemotherapy, radiotherapy; and (3) outcome-related
variables, i.e. vital status, follow-up.
Patients were divided into three age groups: 70–74,
75–79, and C 80 years. The International Classification of
Diseases for Oncology, Third Revision (ICD-O-3) was
used for tumor topography and morphology.18 Pancreatic
cancers were identified through tumor topography codes
(C25.0, C25.1, C25.2, C25.3, C25.7, C25.8, C25.9) and
morphological codes (8000–8009, 8010–8012, 8014–8049,
8050–8089, 8140–8149, 8154, 8158, 8159, 8161,
8163–8169, 8171–8179, 8181–8239, 8244–8245,
8250–8311, 8313–8389, 8440–8499, 8500–8549,
8550–8559, 8560–8579). For NOR, morphological codes
690099 and 699999 (no or unknown microscopic exami-
nation) were also included, since similar patients are coded
as 8000 in the BE and NL cancer registries. Unless patients
with codes 690099 and 699999 were diagnosed by death
certificate only, these patients are not included in the BE
and NL cancer registries.
The 7th edition of the TNM classification was in use
during the study period and was therefore used for tumor
staging in BE and NL.19 pTNM stage was used in patients
who underwent tumor resection and cTNM stage was used
in patients who did not undergo tumor resection. In case of
missing pTNM stage variables for patients who underwent
tumor resection, cTNM stage variables were used when
available. In NOR, tumor stage was categorized as local-
ized, regional, or distant disease. For analyses, localized
and regional tumor disease were included. In case of
missing data on tumor resection, chemotherapy, and
radiotherapy, these categories were classified as ‘no’. No
distinction was made between neo- and adjuvant nonsur-
gical treatment since these data were not available for
NOR. OS was calculated from the day of diagnosis or
tumor resection until the date of death or last follow-up.
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Outcomes and Comparisons
The primary outcome was OS, while secondary out-
comes were tumor resection, 90-day mortality after tumor
resection, and use of nonsurgical treatment strategies [(-
neo)adjuvant and palliative chemotherapy and
radiotherapy]. The main comparison focused on assessing
differences in the three cancer registries. Subgroup analy-
ses were performed comparing each age group between the
cancer registries (in cases of C 60 events).
Statistical Analyses
Statistical analyses were performed using SPSS Inc. for
Windows version 23.0 (IBM Corporation, Armonk, NY,
USA). Categorical data were reported as numbers (per-
centages) and were compared using the Chi square test.
Multivariable binary logistics regression was used to assess
predictive factors (cancer registry, age group) for tumor
resection and 90-day mortality after tumor resection, as
well as use of nonsurgical treatment strategies [(neo)adju-
vant and palliative chemotherapy and radiotherapy] (in
cases of C 60 events). Survival analyses were performed
separately for patients who underwent tumor resection and
patients who did not undergo tumor resection. Kaplan–
Meier curves were used to estimate the median OS and
95% confidence interval (CI), and log-rank tests were used
to compare OS. Multivariable Cox regression was used to
assess predictive factors (cancer registry, age group) for
OS. BE and age group 70–74 years were the reference
categories in the multivariable analyses. Sensitivity anal-
yses were performed, excluding patients who deceased
within 90 days after tumor resection or diagnosis, and
including chemotherapy as an additional factor to assess
the influence on OS and minimize confounding by indi-
cation. In patients who did not undergo tumor resection, a
sensitivity analysis was performed only for patients in
which the tumor was pathologically confirmed. The origi-
nal results were considered robust if the sensitivity
analyses showed similar results. A p value\ 0.05 was
considered statistically significant for all analyses.
RESULTS
Patient and Tumor Characteristics
In total, 3624 patients were included: 1002 (27.6%)
from BE, 1973 (54.4%) from NL, and 649 (17.9%) from
NOR (Table 1). Distribution of sex was comparable
between the cancer registries, and age group distribution
was largely similar. Most tumors were stage II/regional
(72.1% in BE; 67.4% in NL; 72.0% in NOR).
Treatment Strategies
Tumor Resection The tumor resection rate differed
between the cancer registries: 50.2% in BE, 36.2% in
NL, and 41.3% in NOR (p\ 0.001) [Fig. 1a]. Subgroup
analysis showed a similar tumor resection rate in the
70–74 years age group (p = 0.424) and different tumor
resection rates in the higher age groups between the
registries (both p\ 0.001).
In multivariable analyses, patients in NL (odds ratio
[OR] 0.54, 95% CI 0.46–0.65) and NOR (OR 0.65, 95% CI
0.52–0.81) were less likely to undergo tumor resection
compared with BE (Table 2). Patients in the 75–79 years
(OR 0.61, 95% CI 0.51–0.73) and C 80 years age groups
(OR 0.10, 95% CI 0.09–0.13) were less likely to undergo
tumor resection compared with the 70–74 years age group.
Nonsurgical Treatment in Patients Who Underwent Tumor
Resection The use of (neo)adjuvant chemotherapy
differed between the cancer registries: 55.9% in BE,
41.9% in NL, and 13.8% in NOR (p\ 0.001) [Fig. 1b].
Subgroup analysis showed that in all age groups, the use of
(neo)adjuvant chemotherapy differed between the cancer
registries (all p\ 0.001). In multivariable analyses,
patients in NL (OR 0.43, 95% CI 0.34–0.56) and NOR
(OR 0.09, 95% CI 0.06–0.13) were less likely to receive
(neo)adjuvant chemotherapy compared with BE (Table 2).
Patients in the 75–79 years (OR 0.43, 95% CI 0.34–0.55)
and C 80 years age groups (OR 0.10, 95% CI 0.07–0.14)
were less likely to receive (neo)adjuvant chemotherapy
compared with the 70–74 years age group.
TABLE 1 Patient and tumor characteristics by cancer registry
Cancer registry
BE NL NOR
n % n % n %
Total 1002 27.6 1973 54.4 649 17.9
Age group, years 70–74 300 29.9 545 27.6 216 33.3
75–79 310 30.9 564 28.6 166 25.6
C80 392 39.1 864 43.8 267 41.1
Sex Male 458 45.7 894 45.3 295 45.5
Female 544 54.3 1079 54.7 354 54.5
Stagea IA 79 7.9 158 8.0 182 28.0
IB 201 20.1 485 24.6
IIA 226 22.6 552 28.0 467 72.0
IIB 496 49.5 778 39.4
BE Belgian, NL Dutch, NOR Norwegian
a For NOR, no distinction was made for stage IA/IB and IIA/IIB
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The use of (neo)adjuvant radiotherapy was similar
between the cancer registries: 4.0% in BE, 2.2% in NL, and
3.7% in NOR (p = 0.183).
Nonsurgical Treatment in Patients Who Did Not Undergo
Tumor Resection The use of palliative chemotherapy
differed between the cancer registries: 39.5% in BE, 6.0%
in NL, and 15.7% in NOR (p\ 0.001) [Fig. 1c]. Subgroup
analysis showed that in all age groups, the use of palliative
chemotherapy differed between the cancer registries (all
p\ 0.001). In multivariable analyses, patients in NL (OR
0.08, 95% CI 0.05–0.10) and NOR (OR 0.22, 95% CI
0.15–0.32) were less likely to receive palliative
chemotherapy compared with BE (Table 2). Patients in
the 75–79 years (OR 0.54, 95% CI 0.38–0.75)
and C 80 years age groups (OR 0.10, 95% CI 0.07–0.15)
were less likely to receive palliative chemotherapy
compared with patients in the 70–74 years age group.
The use of palliative radiotherapy differed between the
cancer registries: 7.4% in BE, 1.6% in NL, and 0.7% in
NOR (p\ 0.001).
Survival
Ninety-Day Mortality After Tumor Resection Ninety-day
mortality after tumor resection differed between the cancer
registries: 11.7% in BE, 8.0% in NL, and 5.2% in NOR
(p\ 0.001) [Fig. 2]. Subgroup analysis showed different
90-day mortality after tumor resection in the 70–74 years
age group (p = 0.012), and a similar 90-day mortality after
tumor resection in the 75–79 years (p = 0.138)
and C 80 years age groups (p = 0.324) between the
cancer registries. In multivariable analyses, patients in
NL (OR 0.64, 95% CI 0.43–0.95) and NOR (OR 0.38, 95%
CI 0.20–0.72) were less likely to experience 90-day
mortality after tumor resection compared with BE
(Table 3). Age group was not a significant predictive
factor for 90-day mortality after tumor resection.
Overall Survival of Patients Who Underwent Tumor
Resection Median OS in patients who underwent tumor
resection differed between the cancer registries:
17.4 months (15.3–19.4) in BE, 15.9 months (14.4–17.5)
in NL, and 25.4 months (21.6–29.2) in NOR (p\ 0.001)
[Fig. 3a]. Subgroup analysis showed different OS in the
70–74 years age group between the cancer registries, and
similar OS in the 75–79 years and C 80 years age groups
(electronic supplementary Figs. S1a–c). In multivariable
analyses, patients in NL showed similar OS (hazard ratio
[HR] 1.07, 95% CI 0.93–1.22) and patients in NOR showed
better OS (HR 0.72, 95% CI 0.60–0.87) compared with BE
(Table 3). Patients in the 75–79 years (HR 1.23, 95% CI
1.07–1.40) and C 80 years age groups (HR 1.30, 95% CI
1.10–1.54) showed worse OS compared with the
70–74 years age group.
In the sensitivity analysis without patients who deceased
within 90 days after tumor resection, patients who received
(neo)adjuvant chemotherapy showed better OS compared
with (neo)adjuvant chemotherapy-naı¨ve patients; the
results according to cancer registry and age group were
robust (Table 4 and electronic supplementary Table S3).
0
20
40
60
80
100
%
N= 1002 300 310 392 1973 545 564 864 649 216 166 267
BE NL NOR
Cancer registry
0
20
40
60
80
100
%
N= 503 200 196 107 714 353 261 100 268 132  93  43
BE NL NOR
Cancer registry
0
20
40
60
80
100
%
N= 499 100 114 285 1259 192 303 764 381  84  73  224
BE NL NOR
Cancer registry
All
70-74
75-79
>80
All
70-74
75-79
>80
All
70-74
75-79
>80
A
B
C
FIG. 1 Treatment strategies for (a) tumor resection,
(b) (neo)adjuvant chemotherapy, and (c) palliative chemotherapy,
by cancer registry and age group. BE Belgian, NL Dutch, NOR
Norwegian
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Detailed analyses by cancer registry and age group showed
inconsistent results regarding OS of patients who received
(neo)adjuvant chemotherapy versus (neo)adjuvant
chemotherapy-naı¨ve patients (electronic supplementary
Table S4).
Overall Survival of Patients Who Did Not Undergo Tumor
Resection Median OS in patients who did not undergo
tumor resection differed between the cancer registries:
7.0 months (6.2–7.8) in BE, 3.9 months (3.5–4.3) in NL,
and 6.5 months (5.0–8.0) in NOR (p\ 0.001) [Fig. 3b].
Subgroup analysis showed different OS in all age groups
between the cancer registries (electronic supplementary
Figs. S2a–c). In multivariable analyses, patients in NL (HR
1.46, 95% CI 1.31–1.62) and NOR (HR 1.35, 95% CI
1.18–1.55) showed worse OS compared with BE (Table 3),
while patients in the 75–79 years ago group showed similar
OS (HR 1.12, 95% CI 0.97–1.29) and patients in
the C 80 years age group showed worse OS (HR 1.28,
95% CI 1.14–1.44) compared with the 70–74 years age
group.
In the sensitivity analysis without patients who deceased
within 90 days after diagnosis, patients who received pal-
liative chemotherapy did not show better OS compared
with palliative chemotherapy-naı¨ve patients; the results
according to cancer registry and age group were robust
(Table 4 and electronic supplementary Table S3). Detailed
analyses by cancer registry and age group showed
TABLE 2 Multivariable analyses for treatment strategies
Tumor resectiona (Neo)adjuvant chemotherapyb Palliative chemotherapyc
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Cancer BE Reference Reference Reference
Registry NL 0.54 (0.46–0.65) \0.001 0.43 (0.34–0.56) \0.001 0.08 (0.05–0.10) \0.001
NOR 0.65 (0.52–0.81) \0.001 0.09 (0.06–0.13) \0.001 0.22 (0.15–0.32) \0.001
Age group, years 70–74 Reference Reference Reference
75–79 0.61 (0.51–0.73) \0.001 0.43 (0.34–0.55) \0.001 0.54 (0.38–0.75) \0.001
C80 0.10 (0.09–0.13) \0.001 0.10 (0.07–0.15) \0.001 0.10 (0.07–0.14) \0.001
N = 503 200 196 107 714 353 261 100 268 132   93  43
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FIG. 2 Ninety-day mortality after tumor resection, by cancer registry
and age group. BE Belgian, NL Dutch, NOR Norwegian
TABLE 3 Multivariable analyses for survival
90-day mortality after tumor
resectiona
Overall survival of patients who
underwent tumor resectionb
Overall survival of patients who did not
undergo tumor resectionc
OR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Cancer BE Reference Reference Reference
Registry NL 0.67 (0.45–0.98) 0.040 1.07 (0.93–1.22) 0.340 1.46 (1.31–1.62) \0.001
NOR 0.42 (0.23–0.77) 0.005 0.72 (0.60–0.87) 0.001 1.35 (1.18–1.55) \0.001
Age group, years 70–74 Reference Reference Reference
75–79 1.18 (0.79–1.76) 0.433 1.23 (1.07–1.40) 0.001 1.12 (0.97–1.29) 0.111
C80 1.30 (0.79–2.13) 0.307 1.30 (1.10–1.54) 0.002 1.28 (1.14–1.44) \0.001
OR odds ratio, CI confidence interval, HR hazard ratio, BE Belgian, NL Dutch, NOR Norwegian
aNinety-day mortality in patients who underwent tumor resection (n = 1485)
bOverall survival of patients who underwent tumor resection (n = 1485)
cOverall survival of patients who did not undergo tumor resection (n = 2139)
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inconsistent results regarding the OS of patients who
received palliative chemotherapy versus palliative
chemotherapy-naı¨ve patients (electronic supplementary
Table S4). In the sensitivity analysis including patients in
which the tumor was pathologically confirmed, results
regarding cancer registries, age group, and palliative
chemotherapy were robust.
DISCUSSION
In this study, the treatment and survival of patients
aged C 70 years with stage I–II pancreatic cancer were
evaluated in three European population-based cancer reg-
istries. Variations were observed for tumor resection rate
(range 36–50%), (neo)adjuvant chemotherapy (range
14–56%), and palliative chemotherapy (range 6–40%).
Subgroup analysis showed that patients in the 70–74 years
age group had a similar tumor resection rate between the
cancer registries, which was different in the older age
groups. The use of (neo)adjuvant and palliative
chemotherapy was different in all age groups between the
cancer registries. The use of (neo)adjuvant and palliative
radiotherapy was low. Ninety-day mortality after tumor
resection was lower in NL and NOR compared with BE. In
patients who underwent tumor resection, OS in NOR was
better compared with BE, while NL was similar to BE.
Overall, an improved OS was observed in patients who
received (neo)adjuvant compared with chemotherapy-naı¨ve
patients. In patients who did not undergo tumor resection,
OS in BE was better compared with NL and NOR.
Although the TNM staging system is not directly
translatable to widely used resectability criteria,5 the low
resection rate in this study, compared with that previously
reported,20 is noteworthy and could be explained by the
inclusion of patients C 70 years of age. In addition, some
patients may have anatomically resectable disease, yet
have unfavorable biological (high CA19.9) and conditional
(poor functional status) factors.21 An important observation
is that only in the 70–74 years age group was the tumor
resection rate similar between the cancer registries.
According to the ESMO and NCCN guidelines, poor
functional status, but not advanced age, can be a good
reason to be more retained by clinician and patients in their
choice which treatment is most suitable;5,6 however,
unfortunately, no data (e.g. American Society of Anes-
thesiologists [ASA], Eastern Cooperative Oncology Group
[ECOG] score) were available to investigate this. Variation
between the cancer registries regarding the cultural factors
that influence the decision making for treatment in elderly
patients might also be an explanation.22,23 Despite the
higher tumor resection rates in BE and NOR in the older
age groups, which could have illustrated poor patient
selection, 90-day mortality after resection was similar. In
NL only, 90-day mortality after resection increased with
ascending age groups. Possibly, the transparent outcome
indicators (mortality) in the Dutch Pancreatic Cancer
Audit,24 refrains clinicians in NL from performing more
tumor resections. A recent meta-analysis showed elderly
patients have more comorbidities and more overall com-
plications (mainly respiratory), but comparable mortality
compared with younger patients.25 Adequate patient
selection, prehabilitation, enhanced recovery protocols, and
centralization of pancreatic surgery for elderly patients
might improve outcomes.26–30 Others have advocated a
multidisciplinary approach to high-risk elderly patients
undergoing major surgery,31 and several studies have
illuminated the importance of geriatric assessment to
improve the outcomes of cancer treatment.32,33 However,
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high-level evidence regarding functional recovery of
elderly patients undergoing pancreatic surgery is lacking.
Surprisingly, in a Canadian population-based cohort
study,34 age was not a predictive factor for functional
recovery.
The use of (neo)adjuvant chemotherapy was different
between the cancer registries, comparable with previous
international studies.8,15 Nonetheless, this is notable since
adjuvant chemotherapy is the standard treatment.5,6 Mor-
bidity after surgery is not uncommon in elderly patients
and may cause omission of chemotherapy.25,26,35 Unfor-
tunately, these data were not available in the present study.
No distinction was made between neo- and adjuvant
chemotherapy because NOR did not provide this. This was
accepted since the use of neoadjuvant therapy was expec-
ted to be low as the ESMO and NCCN guidelines stated
that neoadjuvant therapy should be used in clinical trials,
and that elderly patients are often not included. The sen-
sitivity analyses showed that the differences between the
cancer registries regarding OS after tumor resection cannot
be explained by the differences in the use of (neo)adjuvant
chemotherapy. It remains unknown which other factors
also contribute to the differences in OS.
The largest observed difference was in the use of pal-
liative chemotherapy between BE (40%) and NL (6%).
This can be explained by the fact that the ESMO and
NCCN guidelines state that palliative treatment can be
considered depending on the performance status of the
patient.5 Differences can also be explained by variations in
nihilistic attitudes of clinicians and patients regarding the
small benefit of palliative chemotherapy in elderly pan-
creatic cancer patients.36 Multiple randomized controlled
trials showed improved OS and quality of life with
palliative chemotherapy, but adverse events are not
rare.9,10 Exemplified by the present study, results from
randomized controlled trials cannot directly be extrapo-
lated to the elderly population due to the strict inclusion
criteria. These factors should be discussed with the patient
before a shared decision on treatment strategy can be made.
In the sensitivity analyses, patients from BE had an
improved OS compared with NL, and similar to NOR,
which suggests that the differences in the use of palliative
chemotherapy do not explain the observed differences in
OS. Furthermore, in sensitivity analyses, palliative
chemotherapy was not a significant predictive factor for
OS. The unclear pattern between (neo)adjuvant and pal-
liative chemotherapy and OS in subgroup analyses suggests
that better patient selection is needed to improve resource
utilization and OS. However, the results also show that
tumor resection and (neo)adjuvant and palliative
chemotherapy, in correctly selected patients, can prolong
survival.
This study has several limitations. First, although the
design and organization of the national cancer registries
was similar, differences in the completeness of data and
patients, which could have influenced the baseline char-
acteristics and results, have to be considered. Baseline
characteristics are of paramount importance for external
validity of study results and should be studied care-
fully.17,37 Our findings may possibly be influenced by
differences in the (under)registration of elderly patients
with pancreatic cancer.38 On the other hand, age distribu-
tion was similar in the cancer registries. Furthermore, the
number of included patients per cancer registry was similar
to the expected number of patients based on the size of the
cancer registry population, the incidence of pancreatic
TABLE 4 Sensitivity analyses for overall survival, excluding patients who deceased within 90 days after diagnosis or tumor resection, by age
group and treatment strategy
Age group, years
Treatment strategy Total 70–74 75–79 C80
n % OS (95%
CI)a
n % OS (95%
CI)a
n % OS (95%
CI)a
n % OS (95%
CI)a
Tumor resection ?
(neo)adjuvant
chemotherapy
602 23.2 22 (19–25) 366 41.6 24 (20–28) 200 24.8 20 (18–23) 36 3.9 21 (13–30)
Tumor resection alone 752 28.9 18 (17–20) 266 30.3 22 (18–26) 298 37.0 16 (14–18) 188 20.5 17 (15–19)
Palliative chemotherapy 293 11.3 9 (8–11) 118 13.4 11 (9–13) 101 12.5 7 (2–12) 74 8.1 10 (8–11)
No treatment 951 36.6 8 (7–9) 129 14.7 12 (10–13) 205 25.5 8 (7–9) 617 67.4 8 (7–9)
Total 2599 100 13 (12–14) 879 100 18 (17–20) 805 100 14 (12–15) 915 100 10 (9–10)
OR odds ratio, CI confidence interval
aMedian overall survival (in months) after tumor resection (patients who underwent tumor resection) or after diagnosis (patients who did not
undergo tumor resection) and 95% CI
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cancer, and the number of incidence years provided. The
proportion of ‘unknown’ stages differed between the can-
cer registries. We hypothesized that this has only
marginally influenced our results. The majority of patients
with ‘unknown stage’ are likely to have stage III–IV dis-
ease and do not undergo further diagnostic procedures due
to poor prognosis at the time of diagnosis. In addition, the
distribution of ‘known’ stages was similar between the
cancer registries. Second, the 7th edition, rather than the
8th edition, of the TNM classification was used in the
analyses due to data availability. As shown by external
validation studies, the 8th edition has more prognostic
significance,39,40 but, on the other hand, was not yet in use
during the study period (2012–2016). Third, this study
included adjusted analyses for age group, but, nevertheless,
residual confounding cannot be ruled out. Due to the low
use of radiotherapy, adjusted analyses were not performed.
In the sensitivity analyses, patients who deceased within
90 days after diagnosis or tumor resection were excluded
and treatment strategies were re-investigated. In patients
who did not undergo tumor resection, the influence of
patients without pathological confirmation was also
investigated. The sensitivity analyses showed that the
original results were robust. Caution must be taken when
drawing conclusions and indicating causal relations
regarding the treatment strategies, since treatment selection
bias cannot be ruled out.
To the best of our knowledge, this is the first study on
elderly patients with stage I–II pancreatic cancer, in three
European cancer registries, that gives insight into real-
world data of treatment strategies and survival. These
outcomes are relevant since the pancreatic cancer popula-
tion is increasing in age and these patients are
underrepresented in clinical trials.7,41 Future studies should
focus on selection criteria for (non)surgical treatment so
that clinicians can offer uniform and tailored treatment
across countries and in (inter)national randomized trials. In
this tailored treatment, quality of life plays a pivotal role
and studies such as the Dutch Pancreatic Cancer Project
(PACAP) will provide valuable data.42
CONCLUSIONS
The treatment and survival of patients aged C 70 years
with stage I–II pancreatic cancer in the EURECCA Pan-
creas Consortium showed substantial variations between
three European registries, including the rate of tumor
resection, (neo)adjuvant chemotherapy, and palliative
chemotherapy. The use of radiotherapy was limited. Sur-
vival of patients who did and did not undergo tumor
resection also differed between the cancer registries. The
findings of this study suggest that patients aged 70 years
and older with stage I–II pancreatic cancer benefit from a
higher tumor resection and chemotherapy administration
rate.
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